IntraBio's AQNEURSA Receives Historic FDA Approval for Niemann-Pick Disease Type C Treatment
IntraBio Inc. has received approval from the FDA for AQNEURSA (levacetylleucine), marking a significant milestone in the treatment of neurological manifestations of Niemann-Pick disease type C in both adults and pediatric patients weighing 15 kg or more. This approval makes AQNEURSA the first FDA-approved stand-alone therapy specifically indicated for NPC, a rare inherited lysosomal disorder affecting approximately 1 in 100,000 live births.
Mallory Factor, President and Chief Executive Officer of IntraBio, expressed enthusiasm about this breakthrough, stating, “In...